Merck & Co. Stock News

Merck trades at a single-digit P/E, reflecting underperformance but strong financials and a robust dividend yield near 3.9%. Keytruda's ongoing success and expanded indications drive near-term results, but loss of exclusivity looms in three years. Merck's pipeline and Verona acquisition position it to offset Keytruda revenue loss, with $50B+ mid-2030s opportunity projected.

Dividend stocks are a great investment choice for many reasons. Buying on the dip is even better, provided, of course, they have the means to bounce back.

The past several months have been bullish ones for the market. But not for every stock.

If you are in your 20's you likely have more than four decades ahead of you to invest before hitting retirement. Some might suggest that now is the time to take an aggressive investment stance, but that could entail more risk than you think.

I rank a selection of undervalued dividend growth stocks in Dividend Radar and present the top ten stocks for consideration. I use two valuation screens, one based on my fair value estimate, and another comparing each stock's forward dividend yield with its 5-year average dividend yield. To rank stocks, I do a quality assessment and sort candidates by quality scores, breaking ties with addition...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-905 trial (also known as EV-303) in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy. In this study, KEYTRUDA® (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv), given bef...

The S&P 500 has a miserly yield of 1.2%. The average healthcare stock's yield is about 1.8%.

If you are looking at healthcare stocks for dividend ideas in August, don't get too caught up on the sector's low 1.8% dividend yield. You can do much better than that without having to take on huge risks.